Establishment and comprehensive analysis of a new human transformed follicular lymphoma B cell line, Tat-1

Leukemia

Volumn 16, Issue 2, 2002, Pages 276-283

  Denyssevych, T ^a   Lestou, V S ^a   Knesevich, S ^a   Robichaud, M ^a   Salski, C ^a   Tan, R D ^a   Horsman, D E ^a   Mayer, L D ^a  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

Apoptosis; Bcl 2; c myc; Non Hodgkin's lymphoma; P gp protein; t(14; 18)

Indexed keywords

CD19 ANTIGEN; CD2 ANTIGEN; CD20 ANTIGEN; CD23 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD5 ANTIGEN; CD7 ANTIGEN; CD8 ANTIGEN; CHLORAMBUCIL; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; GLYCOPROTEIN P; HLA DR ANTIGEN; INHIBITOR OF APOPTOSIS PROTEIN; LYMPHOCYTE SURFACE MARKER; MYC PROTEIN; PREDNISONE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN P53; SDZ PSC 883; TETRAZOLIUM; UNCLASSIFIED DRUG; VALSPODAR; VINCRISTINE;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B CELL LYMPHOMA; CANCER GRADING; CASE REPORT; CHROMOSOME 13Q; CHROMOSOME 8Q; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; CHROMOSOME TRANSLOCATION 1; CHROMOSOME TRANSLOCATION 14; CHROMOSOME TRANSLOCATION 18; CHROMOSOME TRANSLOCATION 8; CONTROLLED STUDY; DRUG ACTIVITY; ENHANCER REGION; EPSTEIN BARR VIRUS; FEMALE; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLICULAR LYMPHOMA; GENE CONTROL; GENE FUSION; GENE PROBE; GENETIC RECOMBINATION; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; LYMPH NODE BIOPSY; LYMPHOCYTE TRANSFORMATION; LYMPHOMA CELL LINE; MALE; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; ONCOGENE C MYC; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; WESTERN BLOTTING;

EID: 0036172021     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2402372     Document Type: Article

References (41)

1. Current treatment of follicular low grade lymphomas
2. Current management of follicular lymphoma
3. Treatment approaches to the low-grade lymphomas
4. Multistep transformation in low-grade lymphoproliferative diseases
5. Cellular and molecular basis of B-cell clonal expansions
6. Changes in Bcl-2 and p53 expression in recurrent B-cell lymphomas
7. High-grade malignant non-Hodgkin's lymphomas differ from low-grade lymphomas in the extent of apoptosis and their expression of bcl-2, mcl-1, bax and p53
8. Comparison of cytogenetic analysis, Southern analysis, and polymerase chain reaction for the detection of t(14;18) in follicular lymphoma
9. Cytogenetic mechanisms in the pathogenesis and progression of follicular lymphoma
10. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death
11. Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgenic for the t(14;18)
12. Multiple recurrent genomic defects in follicular lymphoma: A possible model for cancer
13. Prognostic value of chromosomal abnormalities in follicular lymphoma
14. Cytogenetic evolution patterns in non-Hodgkin's lymphoma
15. Sequential analysis of 43 patients with non-Hodgkin's lymphoma: Clinical correlations with cytogenetic histologic immunophenotyping, and molecular studies
16. Analysis of secondary chromosomal alterations in 165 cases of follicular lymphoma with t(14:18)
17. Guidelines for the characterization and publication of human malignant hematopoietic cell lines
18. The Burkitt-like lymphomas: A Southwest Oncology Group study delineating phenotypic, genotypic, and clinical features
19. Apoptotic induction in transformed follicular lymphoma cells by Bcl-2 downregulation
20. A novel human lymphoma cell line (Deglis) with Dual B/T phenotype and gene rearrangements and containing Epstein-Barr virus genomes
21. Pulsed exposure of SDZ PSC 833 to multidrug resistant P388/ADR and MCF7/ADR cells in the absence of anticancer drugs can fully restore sensitivity to Dox
22. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay
23. Cells. A Laboratory Manual
24. Sequential bcl-2 and c-myc oncogene rearrangements associated with the clinical transformation of non-Hodgkin's lymphoma
25. Concurrent chromosomal alterations at 3q27, 8q24 and 18q21 in B-cell lymphomas
26. Insights from Bcl-2 and Myc: Malignancy involves abrogation of apoptosis as well as sustained proliferation
27. A new B-cell line showing a complex translocation (8;14;18) and BCL2 rearrangement
28. Concurrent activation of MYC and BCL-2 in B cell non-Hodgkin lymphoma cell lines by translocation of both oncogenes to the same immunoglobulin heavy chain locus
29. Abnormalities involving chromosome 6 in newly diagnosed patients with non-Hodgkin's lymphoma
30. Deletions involving two distinct regions of 6q in B-cell non-Hodgkin's lymphoma
31. Acute lymphoblastic leukemia with lymphoproliferative features associated with abnormalities of the short arm of chromosome 9
32. Deregulation of homeobox gene, HOX11, by the t(10;14) in T cell leukemia
33. Apoptosis and cancer chemotherapy
34. Bcl-2, bax and bcl-xL expression in human sensitive and resistant leukemia cell lines
35. Expression and regulation of Bcl-2, Bcl-xl, and Bax correlate with p53 status and sensitivity to apoptosis in childhood acute lymphoblastic leukemia
36. Mutant p53 protein, Bcl-2/Bax ratios and apoptosis in paediatric acute lymphoblastic leukaemia
37. Analysis of Bax and Bcl-2 expression in p53-immunopositive breast cancers
38. Identification of a p53-dependent negative response element in the bcl-2 gene
39. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo
40. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene